ASH 2022 Conference Coverage
Results From a Phase 1/2 Study of Tandem, Bispecific Anti-CD20/Anti-CD19 (LV20.19) CAR T-Cells for MCL
By
ASH 2022 Conference Coverage
FEATURING
Nirav Shah
By
ASH 2022 Conference Coverage
FEATURING
Nirav Shah
Login to view comments.
Click here to Login
